DERMAFILL MD Regulatory Status: A Professional Sourcing Guide

DERMAFILL MD is a hyaluronic acid dermal filler manufactured by CBC MEDICAL in France. Designed for professional aesthetic applications, its profile includes specific formulations developed by a European producer. For clinics and resellers, understanding the regulatory pathway of such products is fundamental to responsible sourcing and practice.

Hyaluronic acid fillers constitute a significant category within aesthetic medicine. As with other products in this segment, such as D.Fill Soft or other items in our Hyaluronic acid dermal filler catalog, DERMAFILL MD is subject to rigorous regulatory oversight to ensure product quality and safety.

The regulatory landscape for medical devices like DERMAFILL MD is governed by international and national standards. Key certifications indicate a product's adherence to safety and quality benchmarks.

• CE Mark (Conformité Européenne): As a French-manufactured product, DERMAFILL MD is expected to possess a CE Mark for sale within the European Economic Area (EEA). This mark designates it as a Class III medical device, subject to stringent assessment. [VERIFY: specific CE Mark status and classification for DERMAFILL MD].
• FDA Approval (United States Food and Drug Administration): For entry into the United States market, DERMAFILL MD would require specific FDA clearance, typically through a 510(k) pathway or Premarket Approval (PMA). [VERIFY: current FDA approval status for DERMAFILL MD for US market entry].
• KFDA (Korean Ministry of Food and Drug Safety): KFDA approval is specific to the South Korean market. [VERIFY: KFDA approval status for DERMAFILL MD].
• GMP (Good Manufacturing Practice) & ISO Certification: CBC MEDICAL, as a medical device manufacturer, is anticipated to operate under GMP guidelines and hold ISO certifications, such as ISO 13485 for Medical Devices Quality Management Systems. [VERIFY: specific GMP and ISO certification details for CBC MEDICAL/DERMAFILL MD].

Regulatory requirements for aesthetic injectables vary significantly across different global markets. Clinics and resellers operating internationally must verify local compliance for DERMAFILL MD.

• European Union (EU) & United Kingdom (UK): The CE Mark is the primary requirement for placement in the EU. Post-Brexit, the UK generally continues to accept the CE Mark, though the UKCA mark may become relevant for new product certifications or specific market entries.
• GCC (Gulf Cooperation Council): Countries like UAE, Saudi Arabia, and Qatar require local health authority registration, which often references EU CE Mark or US FDA approvals as a basis for assessment.
• LATAM (Latin America): Market access in countries such as Brazil (ANVISA), Mexico (COFEPRIS), and Colombia (INVIMA) mandates country-specific registration, often involving local representation and documentation that includes international certifications.
• APAC (Asia-Pacific): This region presents a diverse regulatory landscape, with authorities such as Australia's TGA, Singapore's HSA, and other national bodies setting their own distinct requirements for product registration and import.

The practice of parallel importing, while sometimes legally permissible, carries inherent risks for aesthetic professionals when sourcing medical devices like DERMAFILL MD. These risks include the potential for compromised product quality due to improper storage, lack of traceability, and absence of manufacturer support or warranty.

For products like DERMAFILL MD, ensuring the product originates from authorized channels is crucial. Similar to verifying other aesthetic injectables, such as in our guide on How to Verify Genuine Botulax 100unit for Professional Use, clinics must demand clear evidence of authenticity and a transparent supply chain to mitigate risks.

To ensure compliant sourcing and professional integrity, clinics and resellers should consistently demand specific documentation from their DERMAFILL MD suppliers. This diligence supports both patient safety and adherence to regulatory standards.

Key documents to request include:

• Certificate of Authenticity: Confirming the product's origin and genuine nature.
• Traceable Lot Numbers: Linking each unit to its manufacturing batch for recall or quality assurance purposes.
• Regulatory Clearances: Proof of current market authorization (e.g., CE Mark certificate for EU, local registration documents for other markets).
• Storage and Transport Protocols: Evidence that the product has been handled according to manufacturer guidelines, maintaining integrity from dispatch to delivery.

Understanding these requirements is as vital as the detailed regulatory considerations discussed in Rejuran HB Regulatory Status: A Professional Sourcing Guide.

For professionals planning their stock of DERMAFILL MD, understanding potential wholesale pricing structures is important for inventory management and cost forecasting. While actual pricing can vary based on market conditions and specific agreements, an illustrative wholesale price for DERMAFILL MD might be around $71.0 per unit.

Volume-based pricing tiers are often available to offer efficiencies for larger purchases. For example:

These tiers are provided as an example to assist clinics and resellers in planning their procurement strategies. Final pricing is subject to quotation and order volume.